For Healthcare Professionals

A Study of NB003 in Patients With Advanced Malignancies


About the study

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

Males or females of any race ≥18 years age.

Histologically-confirmed diagnosis of unresectable, relapsed or metastatic GIST or other advanced malignancies.

For dose escalation phase:

  1. GIST patients must have progressed on or had an intolerability to imatinib and other SoCs or refused other SoCs.
  2. Patients with an advanced solid tumor other than GIST must have relapsed or had refractory disease without an available effective therapy and harbor KIT or PDGFRα gene alterations (central laboratory confirmation is not required for screening).

For dose expansion phase:

  1. In the dose expansion phase, additional patients will be enrolled at RP2D to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  3. Life expectancy ≥ 12 weeks.
  4. Adequate organ and marrow function.
  5. Tumor sample collection is required.


Exclusion Criteria:

  1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum wash-out period of 21 days prior to the initiation of study drug administration.
  2. Major surgery within 4 weeks of the first dose.
  3. Radiotherapy with a limited field of radiation for palliation within 1 week prior to the first dose, with the exception as defined.
  4. Patients currently receiving medications or herbal supplements known to be strong inhibitors or inducers of CYP3A4.
  5. Patients currently receiving acid-reducing agents and are unable to stop use at least 2 weeks prior to the first dose.
  6. Any known active central nervous system metastases and/or carcinomatous meningitis. Active infection including hepatitis B, hepatitis C, and HIV.
  7. Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, uncontrolled pericardial effusion, uncontrolled pleural effusion, or any other conditions, which in the judgment of Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
  8. Any evidence of severe or uncontrolled systemic diseases which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Advanced Solid Tumor

Age (in years)



Phase 1

Participants needed


Est. Completion Date

Dec 31, 2025

Treatment type



Ningbo Newbay Technology Development Co., Ltd identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.